Mission
Tissue Genesis, Inc. is an emerging high-growth company
in the field of regenerative medicine, using a patient’s
own cells to coat implants, repair damaged
tissue, heal disease, and other uses. Tissue Genesis
is leveraging its perfusion platform and expertise to
deliver products to the tissue engineering market. Current
near term applications include vascular grafts and wound
healing using patients’ own regenerative cells.
Market Overview
The Regenerative Medicine Revolution
Until recently, physicians essentially had two options–pharmaceutical or surgical–for treating illness, disease or injury. Pharmaceutical solutions, while generally effective, are ubiquitously distributed throughout the body, and can sometimes create unintended side effects. Surgical solutions, using implanted medical devices can also be effective, but may lead to medical complications resulting from rejection of the foreign material by the patient’s immune system.
Thankfully, a third option exists today in regenerative medicine. Tissue Genesis’ technology isolates tens of millions of cells from the patient’s own body that
is believed to accelerate healing and
regenerate damaged tissue.
Human adipose tissue possesses an ample supply of stem cells, microvascular endothelial cells, and other cells. Advanced cell isolation and implementation techniques–such as the ones developed by Tissue Genesis–can unlock the regenerative cells enclosed in adipose tissue, which may re-establish blood flow and increase repair signaling, which promote faster healing.
Because Tissue Genesis’ adipose-derived cell therapy uses the patient’s own cells, the body should more readily accept the therapy; this will be a vast improvement over traditional surgical solutions employing materials foreign to the patient’s immune system.

Potential Uses for Regenerative Cells
• Coating of implantable devices such as vascular grafts and stents
• Repair of tissue damaged by heart disease and peripheral artery disease
• Orthopedic applications
• Cosmetic and reconstructive applications
• Acute and chronic wound repair
• Veterinary applications
|
Highlights
| Founded: |
In 2001, began operations
2002 |
| Employees: |
23 with five PhDs and two MDs |
| Lead Product: |
Tissue Genesis Cell Isolation System |
| Intellectual
Property: |
- Over 43 patents and patent applications.
- Exclusive license to patent portfolio for ASCs developed by Dr. Williams at Thomas Jefferson University.
- Exclusive license to patent portfolio for ASCs developed by Dr. Williams at the University of Arizona.
- Exclusive license to a patent application on the use of ASCs developed by Dr. March at Indiana University.
- Exclusive license to a patent application on the use of ASCs developed by Indiana University.
- Patent issued on a bioculture system, which formed the basis for concepts used in the Tissue Genesis Cell Isolation System.
- Patent applications pending in the U.S. and worldwide on specific inventive aspects of the Tissue Genesis Cell Isolation System.
- Patent applications pending in the U.S. and worldwide on applications of the Tissue Genesis Cell Isolation System.
- Trademark applications pending worldwide on “Tissue Genesis,” “Adipase,” and other product names.
|
| Ownership: |
Privately Held |
| Funding: |
Capital Investment, Contracts and
Grants |
| Exclusive Distributors: |
Bioheart, Inc. (heart), SpineSmith, LP (vairous applicaitons, including the spine, in certain agreed upon medical institutes), and Canine Health Institute (companion dogs in the Houston area) |
.jpg)
Tissue Genesis seeks to advance tissue engineering
and cell therapy solutions that save lives and improve
the quality of life for patients with illness and disease.Our business strategy is to promote the use
of a patients own adipose (fat) derived cells
in repairing damaged tissue and coating of implants. These
cells can be delivered in a wound dressing, or can be
delivered to damaged tissue by means of a catheter or
direct injection, such as injection into damaged heart
tissue. These cells can also be coated onto
implants, such as vascular grafts and stents. In addition
to enabling these applications through its intellectual
property, Tissue Genesis will manufacture operating room
systems for the derivation of these cells from the patient’s
adipose tissue during a medical procedure, leveraging
the company’s versatile enabling platform technology,
to add to the value chain for customers and their patients.
Both our systems and these specific applications represent
significant potential revenue streams for TGI. |